Clinical Trial Update: Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating rituximab plus methotrexate with or without lenalidomide in newly diagnosed primary central nervous system lymphoma (PCNSL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• METHOTREXATE (METHOTREXATE)
• Rituximab (rituximab)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: PCNSL | Phase 2 | Status: UNKNOWN